Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

By sjmartinez • June 4, 2024

Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 3;18(6):885-894. doi: 10.1093/ecco-jcc/jjae007. PMID: 38245818; PMCID: PMC11147797.

Tags: Cedars Sinai DoM, Digestive Diseases, endoscopic improvement–histologic remission, Etrasimod, mucosal healing, Publications, S1P receptor modulator, ulcerative colitis

Exosomes as Future Therapeutic Tools and Targets for Corneal Diseases

Gamez J, Zha D, Ebrahimi SM, White S, Ljubimov AV, Saghizadeh M. Exosomes as Future Therapeutic Tools and Targets for Corneal Diseases. Cells. 2025 Jun[...]

Leveraging A Randomized Trial to Assess Relationships between Transeptal Puncture, Brain Emboli, and Migraine Symptoms

Elias A, Tung R, Gerstenfeld EP, Hue TF, Lin F, Cheng J, Weiss JP, Tzou WS, Hsia H, Ehdaie A, Cooper DH, Bunch TJ, Arkles[...]

The PTPN2 rs1893217 IBD risk allele increases susceptibility to AIEC invasion by a JAK-STAT-CEACAM6 axis

Chatterjee P, Canale V, King SJ, Shawki A, Lei H, Santos AN, Haddad M, Gries C, McGovern DPB, Borneman J, McCole DF. The PTPN2 rs1893217 IBD risk[...]